Artificial Intelligence | 04 December 2024 | News
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has...Read more
Opinion | 01 December 2024 | Views
Indian Lifesciences Industry Going Ahead in its Innovation Journey While Navigating Challenges
India is a major supplier of vaccines, with more than 50 per cent of the world’s vaccines coming from In...Read more
MedTech | 11 December 2024 | News
India’s first CDSCO certified robotic system for telesurgery by SS Innovations to lead the way
The developer of the country’s first indigenous surgical robotic technology, SS Innovations, the visiona...Read more
Start-ups | 11 December 2024 | News
Gurugram-based startup VitusCare, one of India’s fastest-growing dialysis care providers and a leading p...Read more
Supplier | 30 November 2024 | News
Agilent announces launch of Infinity III LC Series and New ProteoAnalyzer System in India
At the 17th edition of CPHI & PMEC India, organised by Informa Markets, from 26 to 28 November at the...Read more
People | 02 December 2024 | News
Entod Pharmaceuticals appoints Dr Anish Desai as Scientific & Research adviser
Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser. Dr Des...Read more
Academics | 30 November 2024 | News
Union Health Ministry has entered into a tripartite Memorandum of Understanding (MoU) with Banaras Hindu Unive...Read more
Text blogs | 01 December 2024 | Views
HIV Prevention Remains Elusive
On December 1, the world gathers every year to commemorate World AIDS Day, which serves as an important remind...Read more
BioPharma’s Transformative & Strategic OUTLOOK 2025
The Indian biopharma industry witnessed notable transformative developments and announcements, marked by innovation, regulatory advancements, and market expansion this year. From achieving global recognition in biosimilars to advancing biomanufacturing capabilities and precision therapeutics, the sector has solidified its role as a key player in the global pharmaceutical landscape. This progress underscores India’s strategic focus on leveraging its robust infrastructure, skilled talent pool, and government support to meet the evolving demands of the healthcare industry. Key developments in 2024 include an increase in biosimilar approvals, enhanced collaborations for biologics and vaccines, and a focus on potential investments in cutting-edge technologies like Artificial Intelligence (AI), continuous manufacturing, and automation through biofoundries. Looking ahead, the industry is well-positioned to align with emerging trends that are shaping the global biopharma landscape for 2025 and beyond. These include the growing emphasis on precision medicine, a shift towards sustainable biomanufacturing practices, and an increase in demand for advanced therapies such as cell and gene therapies. With over $200 billion worth of biologic patents set to expire by 2030, Indian companies are poised to play a pivotal role in driving the next wave of innovation and accessibility in biologics and biosimilars. Let’s explore further.
For Feedback, please email us at: communications@mmactiv.com